Ola Lindén
1 – 20 of 38
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Targeted Alpha Therapy, an Emerging Class of Cancer Agents : A Review
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
(
- Contribution to journal › Article
- 2015
-
Mark
Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women - a Swedish Lymphoma Registry study.
(
- Contribution to journal › Article
-
Mark
Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
2015) In European Journal of Haematology(
- Contribution to journal › Article
-
Mark
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.
(
- Contribution to journal › Article
- 2013
-
Mark
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
(
- Contribution to journal › Article
- 2011
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article
-
Mark
T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
(
- Contribution to journal › Article
-
Mark
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
(
- Contribution to journal › Article
- 2010
-
Mark
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
(
- Contribution to journal › Article
-
Mark
90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
Diversity in antibody-based approaches to non-Hodgkin lymphoma
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry
(
- Contribution to journal › Article
-
Mark
90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma First Results from an International Phase II Clinical Trial
(
- Contribution to journal › Published meeting abstract
-
Mark
Extracorporeal techniques for improving radioimmunotherapy of disseminated malignant tumors
2010)(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2009
-
Mark
Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data.
(
- Contribution to journal › Article
-
Mark
Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib.
(
- Contribution to journal › Letter
- 2008
-
Mark
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
(
- Contribution to journal › Article
-
Mark
Chemorefractory rhabdomyosarcoma treated with radiotherapy, bevacizumab, statins and surgery and maintenance with bevacizumab and chemotherapy.
(
- Contribution to journal › Article
- 2007
-
Mark
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray"
(
- Contribution to journal › Scientific review